Vargas CE, et al. - Among patients treated for prostate cancer, those who received either standard fractionation or hypofractionation proton-beam therapy were compared in terms of quality of life, the American Urological Association Symptom Index (AUA), or adverse events (AEs). Treatment with proton therapy was not only well-tolerated but also afforded excellent quality-of-life scores, persistent low AUA, and no grade 3 or higher AEs on either arm. In addition, no apparent clinical difference was apparent in outcomes with hypofractionated proton-beam therapy compared with standard fractionation.